PetIQ Inc (NASDAQ:PETQ) CFO John Newland sold 11,000 shares of the business’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $31.65, for a total value of $348,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

John Newland also recently made the following trade(s):

  • On Monday, September 17th, John Newland sold 5,500 shares of PetIQ stock. The stock was sold at an average price of $40.76, for a total value of $224,180.00.

Shares of PetIQ stock traded down $0.18 on Thursday, reaching $31.43. 615,100 shares of the company were exchanged, compared to its average volume of 507,296. The firm has a market capitalization of $890.30 million, a PE ratio of 80.59, a price-to-earnings-growth ratio of 1.67 and a beta of 1.52. The company has a quick ratio of 1.10, a current ratio of 2.51 and a debt-to-equity ratio of 0.49. PetIQ Inc has a fifty-two week low of $17.56 and a fifty-two week high of $43.93.

PetIQ (NASDAQ:PETQ) last announced its earnings results on Tuesday, November 13th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.22. The company had revenue of $131.40 million for the quarter, compared to analyst estimates of $125.22 million. PetIQ had a positive return on equity of 11.68% and a negative net margin of 0.12%. PetIQ’s revenue for the quarter was up 116.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.30 earnings per share. Analysts expect that PetIQ Inc will post 0.76 EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. Harvest Fund Management Co. Ltd purchased a new position in shares of PetIQ during the third quarter valued at $135,000. Zions Bancorporation purchased a new position in shares of PetIQ during the third quarter valued at $187,000. Advisory Services Network LLC grew its holdings in shares of PetIQ by 296.0% during the third quarter. Advisory Services Network LLC now owns 4,950 shares of the company’s stock valued at $195,000 after buying an additional 3,700 shares in the last quarter. Engineers Gate Manager LP purchased a new position in shares of PetIQ during the third quarter valued at $200,000. Finally, Cim LLC purchased a new position in shares of PetIQ during the third quarter valued at $204,000. 78.45% of the stock is currently owned by institutional investors.

A number of analysts have recently commented on PETQ shares. SunTrust Banks boosted their price objective on PetIQ to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, August 15th. CL King assumed coverage on PetIQ in a research report on Friday, September 28th. They set a “buy” rating and a $49.00 target price on the stock. Raymond James reaffirmed a “buy” rating and set a $45.00 target price (up from $33.00) on shares of PetIQ in a research report on Wednesday, September 19th. BidaskClub lowered PetIQ from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 15th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of PetIQ in a research report on Friday, August 24th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $41.83.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at

PetIQ Company Profile

PetIQ, Inc operates as a pet health and wellness company. It provides veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.

Featured Story: What are the reasons investors use put options?

Insider Buying and Selling by Quarter for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with's FREE daily email newsletter.